StockWatch
·

JENBURKT PHARMACEUTICALS LTD. Q2 FY27 Results

JENBURPHQ2 FY27 Results
Filing
Result:Weak· Market: Up#Margin squeeze
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue48.3236.1%6.1%
Total Income50.5736.6%6.2%
Expenditure36.2319.8%8.8%
PBT14.34111.8%0.1%
Net Profit10.2173.5%0.5%
OPM26.94%9.97pp1.82pp
NPM20.19%4.29pp1.15pp
EPS23.1373.4%0.4%
View full financials

Revenue grew a modest 6.1% YoY but PAT was effectively flat (+0.5%) as OPM compressed to 26.93% from 28.76% and NPM to 20.19% from 21.34%, with new capex-driven depreciation and finance costs set to keep pressuring margins going forward.

Q2 FY-2027 RESULTS · JENBURPH

Jenburkt Q2 FY27: PAT flat YoY at ₹10.2 Cr as margins compress despite 6% revenue growth

PAT +0.45% YoY · revenue +6.06% · margins compressing

03 Nov 2026 · 3 min read
Revenue

₹48.32 Cr

+6.06% YoY

PAT (standalone)

₹10.21 Cr

+0.45% YoY

Net margin

20.19%

-1.1pp YoY

EPS

₹23.13

Jenburkt's standalone Q2 FY27 revenue rose 6.1% YoY to ₹48.32 Cr, but PAT was effectively flat YoY at ₹10.21 Cr (+0.5%), with EPS at ₹23.13 against ₹23.03 a year ago. Both margins compressed on a YoY basis — OPM to 26.93% from 28.76%, NPM to 20.19% from 21.34% — so the topline gain did not flow through to the bottom line. QoQ the print looks strong (revenue +36.1%, PAT +73.5%), but that is a rebound off an unusually soft Q1 FY27 (₹35.51 Cr revenue, 16.97% OPM) rather than a new growth trend, and should be read that way rather than as momentum.

The scoreboard

Q2 FY-2027 vs prior quarters

Standalone P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹48.32 Cr+36.1%+6.1%
Expenses₹36.23 Cr+19.7%+8.8%
PAT₹10.21 Cr+73.47%+0.45%
Net margin20.19%+4.3pp-1.1pp
EPS₹23.13+73.4%+0.4%

The YoY margin squeeze traces to employee costs up 6.8% (₹14.87 Cr vs ₹13.93 Cr), roughly tracking revenue, but depreciation (+7.4% YoY to ₹0.799 Cr) and finance costs (+20.8% YoY to ₹0.130 Cr) rose faster. Both are tied to a large capex capitalization this quarter: PP&E jumped to ₹65.64 Cr from ₹11.30 Cr at FY26-end as capital work-in-progress fell from ₹46.12 Cr to ₹3.28 Cr, implying a new facility or line went live in the period — a cost step-up that will now run through the P&L each quarter. Separately, the effective tax rate normalized to 28.8% this quarter from Q1 FY27's unusually low 13.1% (a deferred-tax credit then), which is why PAT's QoQ gain (+73.5%) trailed PBT's QoQ gain (+111.8%).

₹
817.03912.531,008.021,103.521,199.0290007-3108-2409-1610-0911-03Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹900, down 3.3% over the past month of trading.

₹ Cr
04.058.112.157.79Q1 FY26rev ₹36 Cr10.16Q2 FY26rev ₹46 Cr5.93Q3 FY26rev ₹43 Cr10.85Q4 FY26rev ₹45 Cr5.89Q1 FY27rev ₹36 Cr10.21Q2 FY27rev ₹48 Cr
Quarterly standalone PAT, ₹ Crore
Beyond the headline

What the summary numbers don't show

Standalone only, single reportable segment (pharma formulations) — no consolidated statement filed

There is no prior management guidance or concall commentary on record for this company, and no analyst/street estimates could be located for this quarter — Jenburkt is an uncovered micro-cap, so vsStreet and vsGuidance are both unknown rather than a miss. No press release or management commentary beyond the bare regulatory filing was available to cross-check against. Among the quarter's other developments, Counter Cyclical Investment crossed a 5% stake (Oct 12) and the stock received NSE trading permission (Sep 22) — both ownership/liquidity items, not P&L drivers — while the Sr VP-International Business resigned (Sep 18) during the quarter, a development worth watching given the company's export exposure, though the filing discloses no segment or geography breakup to size any impact.

  • W1

    Whether the newly capitalized capacity (PP&E now ₹65.64 Cr) lifts H2 FY27 revenue enough to offset the higher depreciation (₹0.799 Cr/qtr) and finance-cost (₹0.130 Cr/qtr) run-rate

  • W2

    Whether Q3 FY27 holds this quarter's revenue/PAT level or reverts toward Q1 FY27's weaker ₹35.51 Cr revenue / ₹5.89 Cr PAT base

  • W3

    Sr VP-International Business resignation (Sep 18, 2026) — watch for any impact on export revenue, which the filing does not break out separately

Standalone only, single reportable segment (pharma formulations), no consolidated statement filed; FY26 annual exceptional item (₹3.95 Cr labour-code impact) sits outside both this quarter and the YoY comparison quarter, which show nil exceptional items; figures converted from ₹ Lacs (÷100).

Informational and educational content only. Not investment advice.